0001140361-21-024961.txt : 20210720 0001140361-21-024961.hdr.sgml : 20210720 20210720163107 ACCESSION NUMBER: 0001140361-21-024961 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210720 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210720 DATE AS OF CHANGE: 20210720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 211101488 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 brhc10027069_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2021

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
   
465 State Route 17, Ramsey, New Jersey
07446
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ADMA
Nasdaq Global Market
Preferred Share Purchase Rights
-
Nasdaq Global Market



Item 8.01
Other Events

On July 20, 2021, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that the United States Food and Drug Administration (“FDA”) recently completed a Pre-Approval Inspection (“PAI”) of the Boca Raton, FL manufacturing facility related to the Company’s application for its VanRx SA25 Workcell aseptic fill-finish machine (“VanRx”).  The PAI successfully concluded with the FDA issuing zero Form 483 observations in the FDA’s determination that the Company’s Boca Raton, FL manufacturing facility continues to operate in compliance with the principles and guidelines of Good Manufacturing Practices standards.  A full copy of the press release it attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01
Exhibits.

(d) Exhibits

Exhibit No.
Description

ADMA Biologics, Inc. Press Release, dated July 20, 2021

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

July 20, 2021
ADMA Biologics, Inc.
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Executive Vice President and Chief Financial Officer


3

EX-99.1 2 brhc10027069_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1


ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021

All Supply Chain Robustness Initiatives Remain on Schedule

RAMSEY, NJ and BOCA RATON, FL – July 20, 2021 – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration (“FDA”) recently completed a Pre-Approval Inspection (“PAI”) of the Boca Raton, FL manufacturing facility related to ADMA's application for its VanRx SA25 Workcell aseptic fill-finish machine (“VanRx”).   The PAI successfully concluded with the FDA issuing zero Form 483 observations in the Agency’s determination that the Company’s Boca Raton, FL facility continues to operate in compliance with the principles and guidelines of Good Manufacturing Practices (“GMP”) standards.  The FDA’s review of ADMA’s VanRx regulatory filing remains ongoing, with anticipated regulatory approval in the second half of 2021.

“Through pandemic-related challenges, the successful completion of the FDA’s PAI for the VanRx demonstrates our continued adherence to GMP standards and speaks to our organization’s continued ability to deliver on regulatory commitments through unprecedented and challenging operating conditions,” said Adam Grossman, President and Chief Executive Officer of ADMA. “With this favorable inspection outcome, we are anticipating receiving approval for the VanRx in the second half of 2021. We would like to thank the FDA for its focused engagement and collaboration in working with ADMA to meet the growing demands of the U.S. immune compromised patient community that relies on plasma-derived immune globulin products for their treatment.”

“The anticipated VanRx approval will provide ADMA with internal fill-finish production capabilities for its commercial products, which is expected to translate into greater patient supply consistency, significant gross margin efficiencies, improved visibility of commercial product lot releases and, consequently, more predictable near-term revenue results.  Additionally, the expected approval will enable ADMA to onboard third-party fill-finish contracts as a new and accretive revenue source.  The COVID-19 pandemic has illuminated the importance and the scarcity value associated with fill-finish manufacturing capabilities and, once approved, we plan to update the market as we explore these potential new business opportunities in the periods ahead,” concluded Mr. Grossman.

The VanRx fill-finish machine utilizes a state-of-the-art closed isolator design, allowing for the removal of human interventions and providing safe drug products for patients.  The VanRx machine has the capability of rapidly switching between different container and closure formats, enabling aseptic filling in a variety of different fill volumes and presentation sizes. The combination of the recently FDA-approved increased BIVIGAM® manufacturing production scale as well as the enhanced vertical integration that will result from the anticipated approval of the VanRx machine will allow ADMA to bring its products to market faster, improve gross margins and substantially increase ADMA’s end-to-end control over its critical manufacturing process.



About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-licensed source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

About BIVIGAM®
 
BIVIGAM (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), including, but not limited to, the following group of genetic disorders: X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency. BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin antibodies. Certain data and other information about BIVIGAM or ADMA and its products can be found on the Company’s website at www.admabiologics.com.
 
Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “anticipate,” “intend,” “target,” “plan,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations; the expected timing of FDA’s approval of ADMA’s VanRx regulatory filing; and the expected commercial, financial and other business benefits in the event of VanRx regulatory approval. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.



COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com



EX-101.SCH 3 adma-20210720.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 adma-20210720_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 adma-20210720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Preferred Share Purchase Rights [Member] EX-101.PRE 6 adma-20210720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 8 brhc10027069_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2021-07-20 2021-07-20 0001368514 adma:PreferredSharePurchaseRightsMember 2021-07-20 2021-07-20 0001368514 us-gaap:CommonStockMember 2021-07-20 2021-07-20 false C/O ADMA BIOLOGICS, INC. 0001368514 0 8-K 2021-07-20 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false false Common Stock ADMA NASDAQ Preferred Share Purchase Rights NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 20, 2021
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 20, 2021
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36728
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One C/O ADMA BIOLOGICS, INC.
Entity Address, Address Line Two 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001368514
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Preferred Share Purchase Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Preferred Share Purchase Rights
Trading Symbol 0
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10027069_8k.htm adma-20210720.xsd adma-20210720_def.xml adma-20210720_lab.xml adma-20210720_pre.xml brhc10027069_ex99-1.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10027069_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "adma-20210720_def.xml" ] }, "inline": { "local": [ "brhc10027069_8k.htm" ] }, "labelLink": { "local": [ "adma-20210720_lab.xml" ] }, "presentationLink": { "local": [ "adma-20210720_pre.xml" ] }, "schema": { "local": [ "adma-20210720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 1, "memberStandard": 1, "nsprefix": "adma", "nsuri": "http://admabiologics.com/20210720", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10027069_8k.htm", "contextRef": "c20210720to20210720", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10027069_8k.htm", "contextRef": "c20210720to20210720", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "adma_PreferredSharePurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Share Purchase Rights [Member]" } } }, "localname": "PreferredSharePurchaseRightsMember", "nsuri": "http://admabiologics.com/20210720", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-21-024961-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-024961-xbrl.zip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end